DZ3461A1 - Pro-medicaments d acides amines excitateurs. - Google Patents

Pro-medicaments d acides amines excitateurs.

Info

Publication number
DZ3461A1
DZ3461A1 DZ013461A DZ013461A DZ3461A1 DZ 3461 A1 DZ3461 A1 DZ 3461A1 DZ 013461 A DZ013461 A DZ 013461A DZ 013461 A DZ013461 A DZ 013461A DZ 3461 A1 DZ3461 A1 DZ 3461A1
Authority
DZ
Algeria
Prior art keywords
amino acid
medicinal products
acid medicinal
exciting amino
exciting
Prior art date
Application number
DZ013461A
Other languages
English (en)
Inventor
David Scott Coffey
James Allen Monn
Steven Wayne Pedersen
Concepcion Pedregal-Tercero
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP01500263A external-priority patent/EP1310480A1/fr
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DZ3461A1 publication Critical patent/DZ3461A1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/12Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C229/50Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms being part of the same condensed ring system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14All rings being cycloaliphatic
    • C07C2602/18All rings being cycloaliphatic the ring system containing six carbon atoms
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Anesthesiology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • AIDS & HIV (AREA)
DZ013461A 2001-01-11 2001-12-21 Pro-medicaments d acides amines excitateurs. DZ3461A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP01500007 2001-01-11
EP01500206 2001-08-02
US32978601P 2001-10-16 2001-10-16
EP01500263A EP1310480A1 (fr) 2001-11-07 2001-11-07 Prodrugs d'aminoacides excitants
PCT/US2001/045866 WO2002055481A1 (fr) 2001-01-11 2001-12-21 Promedicaments d'aminoacides excitateurs

Publications (1)

Publication Number Publication Date
DZ3461A1 true DZ3461A1 (fr) 2002-07-18

Family

ID=27440162

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ013461A DZ3461A1 (fr) 2001-01-11 2001-12-21 Pro-medicaments d acides amines excitateurs.

Country Status (24)

Country Link
US (1) US7256217B2 (fr)
EP (1) EP1368304B1 (fr)
JP (1) JP4064237B2 (fr)
KR (1) KR20030090622A (fr)
CN (1) CN1267407C (fr)
AR (1) AR036007A1 (fr)
AT (1) ATE356111T1 (fr)
AU (1) AU2002228737B2 (fr)
BR (1) BR0116770A (fr)
CA (1) CA2433667C (fr)
CZ (1) CZ303490B6 (fr)
DE (1) DE60127182T2 (fr)
DZ (1) DZ3461A1 (fr)
ES (1) ES2282315T3 (fr)
HU (1) HUP0400620A3 (fr)
IL (1) IL156364A0 (fr)
MX (1) MXPA03006186A (fr)
NO (1) NO20033166L (fr)
NZ (1) NZ526050A (fr)
PE (1) PE20020829A1 (fr)
PL (1) PL208413B1 (fr)
SK (1) SK287934B6 (fr)
SV (1) SV2003000836A (fr)
WO (1) WO2002055481A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1517915E (pt) * 2002-06-11 2009-04-09 Lilly Co Eli Pró-drogas de amino ácidos de excitação
WO2010111080A2 (fr) 2009-03-27 2010-09-30 Eli Lilly And Company Traitement optimisé de la schizophrénie
JO2978B1 (en) * 2009-12-21 2016-03-15 ايلي ليلي اند كومباني MGLU2 aids
PT2721012T (pt) 2011-06-17 2016-07-27 Lilly Co Eli Derivados do ácido biciclo(3.1.0)hexano-2,6¿dicarboxílico como agonista do recetor mglu2
AR089718A1 (es) 2012-02-01 2014-09-10 Lilly Co Eli AGONISTAS DE mGlu2/3
MX2020010937A (es) 2018-04-17 2020-11-06 Bayer Ag Metodo para la preparacion de esteres de aminoacidos n-acilados con funciones de grupo protector cetona labil al acido.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL182285B1 (pl) * 1994-08-12 2001-12-31 Lilly Co Eli Syntetyczne aminokwasy oraz ich estry i srodki farmaceutyczne je zawierajace PL PL PL PL PL PL PL
US5750566A (en) * 1994-08-12 1998-05-12 Eli Lilly And Company Synthetic excitatory amino acids
PT776201E (pt) * 1994-08-12 2002-03-28 Lilly Co Eli Composicao e metodo para tratar a ansiedade
IL118727A (en) * 1995-06-29 2003-01-12 Lilly Co Eli (-)-2-spiro-5-hydantoinbicyclo [3.1.0] hexane-6-carboxylic acid, salts thereof and use thereof for the preparation of (+)-(2) aminobicyclo [3.1.0] hexane-2,6-dicarboxylic acid
ZA983930B (en) * 1997-05-14 1999-11-08 Lilly Co Eli Excitatory amino acid receptor modulators.
ES2191412T3 (es) 1998-01-28 2003-09-01 Taisho Pharmaceutical Co Ltd Derivados de aminoacidos que contienen fluor.
GB9815542D0 (en) 1998-07-17 1998-09-16 Lilly Co Eli Bicyclohexane derivatives
US6528499B1 (en) 2000-04-27 2003-03-04 Georgetown University Ligands for metabotropic glutamate receptors and inhibitors of NAALADase
WO2002055485A1 (fr) 2001-01-11 2002-07-18 Eli Lilly And Company Promedicaments d'acides amines excitateurs
EP1423411A2 (fr) 2001-07-09 2004-06-02 Eli Lilly And Company Promedicaments d'acides amines excitateurs
WO2003045898A1 (fr) 2001-11-23 2003-06-05 Eli Lilly And Company Promedicaments d'acides amines excitateurs
WO2003057661A1 (fr) 2001-12-21 2003-07-17 Eli Lilly And Company Promedicaments a base d'acides amines excitateurs

Also Published As

Publication number Publication date
SK287934B6 (sk) 2012-05-03
NZ526050A (en) 2005-03-24
PL361669A1 (en) 2004-10-04
CA2433667A1 (fr) 2002-07-18
ATE356111T1 (de) 2007-03-15
SV2003000836A (es) 2003-01-13
CZ20031916A3 (en) 2004-03-17
JP4064237B2 (ja) 2008-03-19
NO20033166D0 (no) 2003-07-10
WO2002055481A1 (fr) 2002-07-18
HUP0400620A3 (en) 2012-09-28
EP1368304B1 (fr) 2007-03-07
ES2282315T3 (es) 2007-10-16
EP1368304A1 (fr) 2003-12-10
CN1486298A (zh) 2004-03-31
AR036007A1 (es) 2004-08-04
US20040121962A1 (en) 2004-06-24
BR0116770A (pt) 2003-12-23
KR20030090622A (ko) 2003-11-28
AU2002228737B2 (en) 2007-01-04
DE60127182D1 (de) 2007-04-19
PE20020829A1 (es) 2002-09-21
JP2004524292A (ja) 2004-08-12
CZ303490B6 (cs) 2012-10-17
NO20033166L (no) 2003-09-09
PL208413B1 (pl) 2011-04-29
IL156364A0 (en) 2004-01-04
SK8262003A3 (en) 2004-01-08
MXPA03006186A (es) 2004-02-13
CA2433667C (fr) 2011-06-14
HUP0400620A2 (hu) 2004-12-28
US7256217B2 (en) 2007-08-14
CN1267407C (zh) 2006-08-02
DE60127182T2 (de) 2007-11-22
WO2002055481A8 (fr) 2003-10-02

Similar Documents

Publication Publication Date Title
NO20033556D0 (no) Farmasöytiske preparater
NO20033384D0 (no) Farmasöytisk formulering
NO20041315L (no) Medikamentavleveringssystem
NO20033785L (no) Farmasöytisk formulering
DK1405852T3 (da) Diaminderivater
EE05267B1 (et) Antraniilhappe amiidid, nende kasutamine ja farmatseutiline preparaat
EE200300369A (et) Atsüülitud indanüülamiinid, nende valmistamismeetod, kasutamine ja farmatseutiline preparaat
PT1501534E (pt) Formulacoes farmaceuticas
ATE555809T1 (de) Pharmezeutische anti-tnf-alpha antikörper formulierung
DK1545662T3 (da) Lægemiddelindgivelsessystem
GB0012850D0 (en) Cyclic amino acid derivatives useful as pharmaceutical agents
IS7798A (is) Efnasambönd, lyfjablöndur og aðferðir
NO20035627D0 (no) Farmasöytisk formulering
NO20035315D0 (no) Farmasöytiske kombinasjoner
DE60217089D1 (de) Lipidsenkende biphenylcarbonsäureamide
NO20042502L (no) Farmasoytisk formulering omfattende bicalutamid
NO20041485L (no) Farmasoytisk formulering omfattende (R)-bicalutamid
DZ3461A1 (fr) Pro-medicaments d acides amines excitateurs.
NO20042890L (no) Farmasoytiske preparater og fremgangsmate for fremstilling derav
DK1429753T3 (da) Farmaceutisk sammensætning omfattende gamma-butyrobetain
NO20015534D0 (no) Farmasöytisk blandeapparat
FI20012242A0 (fi) Uudet farmaseuttiset yhdisteet
NO20041236L (no) Farmasoytisk formulering
FI20011195A (fi) Menetelmä ekstensiotuotteiden määrittämiseksi
SE0101171D0 (sv) Pharmaceutical formulation